WILMINGTON, Del. — Delaware-based global water technologies leader Solenis has chosen its hometown of Wilmington as the site for a $40 million research and development expansion.

In response to increasing market demand for its sustainability-focused products and expertise and with an eye toward long-term growth, Solenis will expand its R&D operations with a move to the 100,000-square-foot Building 713 at Chestnut Run Innovation and Science Park (CRISP). CRISP is a former DuPont campus that MRA Group is developing into a hub for a range of life sciences and advanced chemical companies.

Solenis is a global leader in supplying innovative specialty chemicals and services for process, functional, and water treatment applications to consumer and industrial markets.

The new CRISP facility will provide Solenis with 20,000 square feet more lab space than the company currently has at its existing R&D center on Ashland’s Wilmington campus. In addition to more space, the larger, upgraded site will allow Solenis to add up to 46 new highly skilled Delaware jobs — including lab technicians, scientists and R&D supervisors — within the next three years.

“Solenis chose to build their global water technologies in Wilmington. This week’s announcement shows their continued commitment to our state and workforce,” said Governor John Carney. “Solenis will expand its research and development operations to a 100,000-square-foot building. Thank you to Solenis for continuing to strengthen Delaware’s workforce and science and technology sector.”

Solenis is a vital part of Delaware’s science and technology sector and is a significant Delaware employer. Choosing to invest in a new facility in Wilmington will provide Solenis with the opportunity to grow its R&D team to support projected growth while solidifying its commitment to Delaware.

Originally spun off from Ashland and headquartered at Wilmington’s Avenue North since 2020, Solenis has 48 manufacturing facilities and more than 6,400 employees around the world to serve an array of industries in 120 countries. Solenis currently employs more than 300 in Delaware, with approximately 185 employees at the Avenue North headquarters and 140 employees at its Ashland R&D site. Both are located in Northern Delaware’s New Castle County.

“What the MRA Group has done for the CRISP campus is transformative for our County,” said New Castle County Executive Matt Meyer. “The redeveloped campus gives our existing Delaware companies that are expanding a home to grow and thrive. New Castle County is proud to continue to be the home of Solenis, which provides great jobs in our community producing innovative and sustainable solutions for everyday life.”

Solenis officials presented an application to Delaware’s Council on Development Finance (CDF) for a Jobs Performance Grant of $552,000 and a Delaware Lab Space Grant of $3.5 million from the Delaware Strategic Fund to support the company’s investment of $40 million. Distribution of grants from the Delaware Strategic Fund are dependent on the company meeting commitments as outlined to the CDF, which reviewed and approved the Solenis team’s request for up to $4.052 million in total grant funding.

“Solenis has deep roots in Delaware, so we are pleased to announce our continued commitment to growing in the state at CRISP,” said John Panichella, CEO, Solenis. “This investment of moving our Wilmington research center to a contemporary new location, in combination with our recently opened headquarters at Avenue North, allows us to continue to attract, retain and recruit the highest caliber of employees.”

###

About Delaware Prosperity Partnership

Delaware Prosperity Partnership leads Delaware’s economic development efforts to attract, grow and retain businesses; to build a stronger entrepreneurial and innovation ecosystem; and to support employers in place marketing Delaware to potential employees via livelovedelaware.com. The DPP team works with site selectors, executives and developers focused on where to locate or grow a business and helps with reviewing potential sites, cost-of-living analyses and funding opportunities, including available tax credits and incentives. DPP advances a culture of innovation in Delaware, working with innovators and startups to spotlight and celebrate successes and connect them with the resources they need to succeed. DPP and its partnerships throughout Delaware support and advance the missions of companies of all sizes and sectors.

About Solenis

Solenis is a leading global producer of specialty chemicals focused on delivering sustainable solutions for water-intensive industries, including the pulp, packaging paper and board, tissue and towel, oil and gas, petroleum refining, chemical processing, mining, biorefining, power, municipal, and pool and spa markets. Owned by Platinum Equity, the company’s product portfolio includes a broad array of water treatment chemistries, process aids and functional additives, as well as state-of-the-art monitoring and control systems. These technologies are used by customers to improve operational efficiencies, enhance product quality, protect plant assets, minimize environmental impact and maintain healthy water. Headquartered in Wilmington, Delaware, the company has 48 manufacturing facilities strategically located around the globe and employs a team of over 6,400 professionals in 120 countries across five continents. Solenis is a 2022 US Best Managed Company. For additional information about Solenis, please visit www.solenis.com or follow us on social media.

Stay Up To Date With Delaware

WILMINGTON, Del. – Uvax Bio LLC, an early-stage biopharmaceutical company with cutting-edge vaccine platform technology that has produced both COVID-19 and HIV-1 vaccine candidates, has chosen to grow in Newark, Delaware, where it has been headquartered since forming in 2018.

As part of its expansion, Uvax Bio plans to add 63 employees to its current five-member team. Positions will range from research associates to executive-level research directors with minimum salaries ranging from $45,000 to more than $130,000.

“Uvax Bio LLC is an innovative company in the science and technology sector, specializing in vaccine platform technology. Today’s announcement to grow in Newark shows their continued commitment to our state and workforce,” said Governor John Carney. “Uvax Bio plans to increase their employees tenfold with this expansion. Thank you to Uvax Bio for their commitment to Delaware’s rapidly growing life sciences sector.”

To accommodate its next level of growth, the company has relocated to 100 Biddle Avenue in Springside Plaza off Route 40. Plans there include renovating the site’s existing wet lab and office space into a facility ideal for achieving the company’s goal of developing vaccines that support public health and improve life.

Uvax Bio is an innovative part of Delaware’s rapidly growing life sciences sector. The company maintains vital partnerships with Newark-based, internationally known industry players such as the National Institute for Innovation in Manufacturing Biopharmaceuticals and the University of Delaware.

“New Castle County is proud to be home of another life sciences company that is providing life-changing vaccines for the world,” said New Castle County Executive Matt Meyer. “Uvax is a great example of when science and innovation merge into solutions that will save lives.”

Uvax Bio was formed to develop and commercialize next-generation vaccines to address infectious diseases that threaten global health. Uvax Bio holds an exclusive license agreement with California-based nonprofit biomedical research facility Scripps Research that covers 11 patented and proprietary 1c-SApNP® vaccines. The company’s platform technology is based on computational biology and rational design. These cutting-edge scientific tools were used to design the Uvax, an all-in-one, viruslike nanoparticle design and a one-for-all, simple manufacturing process invented by Uvax Bio co-founder and Chief Scientific Officer Jiang Zhu, Professor of Scripps Research.

The opportunity for Uvax Bio to take their two lead vaccine candidates for COVID-19 and HIV-1 into Phase 1 trials represents a major milestone for the company. While the company’s two lead candidates are entering human trials, Uvax plans to raise additional capital in order to advance other promising new vaccine candidates toward Phase 1 readiness.

During today’s meeting of Delaware’s Council on Development Finance, Uvax Bio officials presented an application for a Jobs Performance Grant of up to $1,061,955 and a Capital Expenditures Grant of up to $240,000 from the Delaware Strategic Fund. Distribution of grants from the Delaware Strategic Fund are dependent on the company meeting commitments as outlined to the CDF, which reviewed and approved Uvax Bio’s request for up to $1,301,955 in total grant funding.

“The team at Uvax Bio is passionate about our mission to design and deliver groundbreaking vaccines to address global threats from infectious disease,” said Ji Li, Ph.D., Uvax CEO. “We are very excited to build a team of talented scientific, business and administrative professionals right here in the Newark, Delaware, area!”

###

About Delaware Prosperity Partnership

Delaware Prosperity Partnership (choosedelaware.com) leads Delaware’s economic development efforts to attract, grow and retain businesses; to build a stronger entrepreneurial and innovation ecosystem; and to support employers in place marketing Delaware to potential employees via livelovedelaware.com. The DPP team works with site selectors, executives and developers focused on where to locate or grow a business and helps with reviewing potential sites, cost-of-living analyses and funding opportunities, including available tax credits and incentives. DPP advances a culture of innovation in Delaware, working with innovators and startups to spotlight and celebrate successes and connect them with the resources they need to succeed. DPP and its partnerships throughout Delaware support and advance the missions of companies of all sizes and sectors.

About Uvax Bio

Founded in early 2018, Uvax Bio, a spinoff vaccine company from Scripps Research, employs proprietary 1c-SApNP® platform technology developed by Dr. Jiang Zhu of Scripps Research to develop and commercialize prophylactic vaccines for the most challenging infectious diseases. Uvax Bio’s mission is working to solve the world’s infectious disease threats by combining rational antigen design and protein engineering to create viruslike particle vaccines. Its vision is to become a global leader in the vaccine industry and offer vaccine solutions for unmet public health needs.

Stay Up To Date With Delaware

WILMINGTON, Del. – Versogen, an industry-leading green energy startup, has chosen Delaware as the site for a $4.8 million expansion that includes moving its operations from The Innovation Space in Wilmington, Delaware, to larger, upgraded facilities at FMC Stine Research Center in Newark, Delaware.

Versogen targets deep decarbonization of the sectors of our economy that are not possible by green electricity. The startup is focused on anion-exchange membranes (AEMs) and AEM based electrolyzers to produce low-cost green hydrogen at scale. The company’s systems are engineered to make green hydrogen affordable and sustainable – from the materials used in manufacturing through to the costs of operations.

“Delaware has been a hub for innovation for decades. Versogen is the latest success out of Delaware’s Innovation Space and a great example of the collaborative environment we have for economic development in our state,” said Governor John Carney. “We are excited for Versogen’s expansion, bringing new jobs and important technologies to New Castle County.”

Versogen’s investment includes renovating Stine Building 115 and creating additional lab space at the site, which will be fully operational by 2024. The company’s relocation will accommodate its next level of operations, which includes adding forty-nine new jobs over the next three years to the 16 positions currently staffing the company.

“New Castle County is the ideal place for startup companies like Versogen to create innovative green technologies,” said New Castle County Executive Matt Meyer. “We are proud to welcome Versogen and know that it will find the first-rate talent for employees and further growth.”

Officials from FMC agreed.

“At the FMC Stine Research Center, we work hard to change the world for the better,” said Dr. Kathleen Shelton, FMC executive vice president and chief technology officer. “We are excited to welcome Versogen and applaud them for developing industry-leading green energy technologies. We appreciate Delaware Prosperity Partnership for the continued collaboration and actively building a strong entrepreneurial and innovation ecosystem in the State of Delaware.”

Versogen officials presented today to Delaware’s Council on Development Finance the company’s application for a Delaware Lab Space Grant of $450,380 and a Jobs Performance Grant of $151,343 from the Delaware Strategic Fund to support the company’s investment of more than $4.8 million. Distribution of grants from the Delaware Strategic Fund are dependent on the company meeting commitments as outlined to the CDF, which reviewed and approved Versogen’s request for up to $601,723 in total grant funding.

“Versogen has been strongly supported by the State of Delaware directly or indirectly from its inception,” said Yushan Yan, Versogen co-founder and CEO. “The grants approved today for Versogen from the Delaware Strategic Fund demonstrate Delaware’s unwavering commitment to building a vibrant entrepreneurial environment for startups and to providing critically needed facilities grants for them to grow.”

Versogen began with research conducted in Yan’s lab in his role as Henry B. du Pont Chair of Chemical and Biomolecular Engineering at the University of Delaware. As Yan said, Delaware recognized the startup’s promise right away. So did entities throughout the United States, with numerous supporting the company’s work to bring to market a new class of polymer membranes that will make green hydrogen and fuel cells more economical.

Originally branded as W7 Energy and rebranded as Versogen in 2021, the company has been supported by more than $5 million in grants. These include the prestigious BIRD Project grant in 2020 and selection as one of three startups for the fourth cohort of the Shell GameChanger Accelerator (GCxN) program in 2021.

Earlier this year, Versogen closed a Series A funding round that raised $14.5 million. This investment allows the company to scale development of its low-cost green hydrogen electrolyzer stacks.

###

About Delaware Prosperity Partnership

Delaware Prosperity Partnership leads Delaware’s economic development efforts to attract, grow and retain businesses; to build a stronger entrepreneurial and innovation ecosystem; and to support employers in place marketing Delaware to potential employees via livelovedelaware.com. The DPP team works with site selectors, executives and developers focused on where to locate or grow a business and helps with reviewing potential sites, cost-of-living analyses and funding opportunities, including available tax credits and incentives. DPP advances a culture of innovation in Delaware, working with innovators and startups to spotlight and celebrate successes and connect them with the resources they need to succeed. DPP and its partnerships throughout Delaware support and advance the missions of companies of all sizes and sectors.

About Versogen

Versogen is an industry-leading green energy startup founded by Yushan Yan, the Henry B. du Pont Chair of Chemical and Biomolecular Engineering at the University of Delaware and a member of the National Academy of Engineering. The company’s focus is decarbonizing heavy, hard-to-abate carbon by producing low-cost green hydrogen with its zero-emission AEM electrolyzer that uses natural materials, water and renewable energy to produce hydrogen at scale. Versogen systems are engineered to make green hydrogen affordable and sustainable – from the materials used in manufacturing right through to the costs of operations.

Stay Up To Date With Delaware